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Abstract
Background: Radiation therapy is the method of choice for subjects with inoperable salivary gland malignancies. I-
125 brachytherapy, delivering a high radiation dose to a tumor but sparing surrounding normal tissues, is supposed
to be ideal modality for the treatment of salivary gland malignancies. We designed a randomised controlled clinical
trial to compare the efficacy of I-125 permanent brachytherapy (PBT) versus intensity-modulated radiation therapy
(IMRT) for inoperable salivary gland malignancies.
Methods/Design: In this study, inclusion criteria are subjects with inoperable salivary gland malignancies, aged 18–
80 years, have provided informed consent, with at least one measurable tumor focus, be able to survive
≥3 months, Karnofsky performance status ≥60, have adequate hematopoietic function of bone marrow, have
normal liver and kidney function, and are willing to prevent pregnancy.
Exclusion criteria include a history of radiation or chemotherapy, a history of other malignant tumors in the past
5 years, receiving other effective treatments, participating in other clinical trials, with circulatory metastasis, cognitive
impairment, severe cardiovascular and cerebrovascular diseases, acute infection, uncontrolled systemic disease,
history of interstitial lungdisease, and being pregnant or breast feeding.
The study will be conducted as a clinical, prospective, randomised controlled trial with balanced randomisation (1:1).
The planned sample size is 90 subjects. Subjects with inoperable salivary gland malignancies are randomised to receive
either I-125 PBT or IMRT, with stratification by tumor size and neck lymph node metastasis. Participants in both groups
will be followed up at 2, 4, 6, 9, 12, 15, 18, 21 and 24 months after randomization. The primary outcome is local control
rate of the primary site (based on imaging findings and clinical examination, RECIST criteria) in 1 year. Secondary
outcomes are progression-free survival, overall survival, quality of life (QOL) measured with the European Organization
for Research and Treatment of Cancer QOL Questionnaire (EORTC QLQ-C30 and QLQ-H&N35) of Chinese version, and
safety of treatment. Chi-squared test is used to compare the local control rates in both groups. The survival curves are
estimated by the Kaplan-Meier method, and log-rank test is used to test the significant difference.
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Discussion: Only few observational studies have investigated the effect of I-125 PBT on inoperable salivary gland
malignancies. To our knowledge, this is the first randomised controlled trial to investigate the efficacy of I-125 PBT for
subjects with inoperable salivary gland malignancies, and will add to the knowledge base for the treatment of these
subjects.
Trial registration: The study is registered to Clinical Trials.gov (NCT02048254) on Jan 29, 2014.
Keywords: I-125 permanent brachytherapy, Intensity-modulated radiation therapy, Inoperable salivary gland
malignancy, Local control rate, Quality of life
Background
Primary malignant tumors of the major and minor saliv-
ary glands are relatively rare entities, accounting for only
about 3–5 % of all head and neck malignancies. They
also contain a diverse group of histologies, with dispar-
ate characteristics in terms of aggressiveness and pat-
terns of spread [1]. Surgery has historically been the
mainstay of treatment for salivary gland malignancies.
Subjects with low-grade tumors are usually treated with
surgery alone if complete excision can be achieved.
Radiotherapy, as a postoperative adjunct to surgery, has
traditionally been reserved for subjects with microscop-
ically high-grade tumors, positive margins or nerve inva-
sion. Although carcinomas originating from the salivary
glands were previously thought to be radioresistant, the
role of adjunct radiotherapy in therapy has become well
recognized [2, 3]. However, the therapy for inoperable ma-
lignant salivary has been extremely challenging in clinical
practice: some subjects are either not candidates for defini-
tive resection or undergo limited procedures leaving behind
gross residual disease. Typically, these subjects are deemed
inoperable because of technical issues related to the exten-
siveness or location of the primary tumor. Another subset
of inoperable subjects present with medical comorbidities
that places them at unacceptably high risk for perioperative
complications. Lastly, some subjects refuse surgical therapy
out of personal preference. For whatever reason, these
inoperable subjects have all traditionally been offered de-
finitive radiation therapy as an alternative to surgery. Unfor-
tunately, the reported results following low linear energy
transfer (LET) irradiation are poor, with overall local con-
trol rates average below 30 % [4–10]. In a multicenter ran-
domised controlled study conducted by the American
Radiation Therapy Oncology (RTOG) and the UK Medical
Research Council (MRC), the 2-year local control rate
(LCR) of unresectable salivary gland cancers with conven-
tional external radiotherapy was only 17 % [10].
The dose response of biological systems is influenced
by the LET of ionizing radiation. In general, relative
radiobiological effectiveness (RBE) increases with LET.
A number of studies have been carried out to investigate
the effectiveness of high-LET RT such as fast neutron
RT. Batterman et al. described an elevated RBE for fast
neutrons in the treatment of lung metastases of malig-
nant salivary gland tumors. In this study, the highest
RBE values up to 8 were found for ACC [11]. The rando-
mised controlled study conducted by RTOG and MRC
showed that the 2-year local control rate was 67 % for fast
neutron radiotherapy compared with 17 % for conven-
tional photon radiation [10]. However, the indication of
fast neutron radiotherapy has been strictly limited because
of its unacceptable damage to the surrounding normal tis-
sues [12, 13]. In heavy particles radiotherapy, carbon ions
have similar radiobiologic properties as neutrons, and
higher RBE values can be expected for salivary gland
tumors. Compared with neutron RT, carbon ions add-
itionally provide physical selectivity due to an inverse dose
profile. Thus, carbon ions was considered to have poten-
tially greater clinical value [14]. In Germany, intensity-
modulated radiation therapy (IMRT) combined with car-
bon ions radiotherapy was recommended as the standard
treatment for inoperable salivary gland malignancies [15].
But carbon ions radiotherapy was expensive and unavail-
able, which obviously limits its application.
Brachytherapy is an important modality in the treatment
of human malignancy with ionizing radiation. Where ap-
plicable, it may be the method of choice for the following
reasons [16, 17]. First, the localized dose distribution en-
hances the ratio of tumor dose to surrounding normal tis-
sue dose. Second, the reduction of oxygen enhancement
ratio and dose rate may partially circumvent the radiore-
sistance of hypoxic tumor cells. Permanent implants of I-
125 sources in focus sites have been widely used, espe-
cially for prostatic cancer [18]. Because LET increases with
decreasing photon energy, I-125 source with low energy
photons(average 28 keV) has higher RBE values (approxi-
mately 1.4) [19]. In addition, the low photon energy also
provides more sparing for adjacent normal tissue and easy
resolution of the problem of protecting medical staff from
radiation exposure. Some studies have shown that I-125
permanent brachytherapy (PBT) may have potential
advantages in local control of salivary gland malignancies
and in minimizing radiobiological damage to normal adja-
cent tissues [20–24]. I-125 has a long half-life of 60 days
and may be ineffective in eradicating tumors with fast
growth kinetics [25–27]. The clinical efficacy of I-125 in
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prostatic cancer may be due to the relative slow prolifera-
tive rate of this disease [25–27]. Like prostatic cancer,
many of salivary gland malignancies are characteristically
slowly proliferating tumours with long natural histories.
Therefore, I-125 is supposed to be ideal modality for the
treatment of salivary gland malignancies, as suggested by
other nonrandomised clinical trials. In order to obtain
more credible evidence, we launch a Phase III, randomised
controlled trial to compare the efficacy of I-125 PBT ver-
sus IMRT for inoperable salivary gland malignancies.
Methods and design
Trial design and setting
The study is conducted as a single center, prospective, ran-
domised controlled trial with balanced randomisation (1:1)
for subjects who have inoperable malignant salivary gland
tumors are randomised to receive either I-125 PBT or
IMRT. Subjects are stratified by tumor size (≤4 cm vs.
>4 cm) and neck lymph node metastasis (yes vs. no).
Subjects are recruited continuously by oncologists at
Department of Oral and Maxillofacial Surgery, Peking
University School and Hospital of Stomatology which is the
only department to treating salivary gland malignancies by
I-125 PBT in China.
Ethical approval
The protocol and informed consent form have been
reviewed and approved by the Institutional Review
Boards of the Peking University Health Science Center
in Beijing, China, and registered at www.clinicaltrials.gov
(NCT02048254). Figure 1 illustrates the flow diagram of
the study for both the intervention and control groups.
Participants
Ninety subjects will be recruited for the study and di-
vided into an intervention group (I-125 PBT) and a con-
trol group (IMRT).
Inclusion criteria
In the study, inclusion criteria are as follows: (1) willing
to participate and sign informed consent; (2) aged 18–80
years; (3) malignancies originating from major or minor
salivary glands based on pathological and/or cytological
diagnosis, including primary or recurrent tumors; (4)
with inoperable tumors, including unresectable primary
locally advanced tumors; unresectable recurrent tumors;
and unable to undergo surgery due to other medical co-
morbidities or refusal of surgery out of personal prefer-
ence, and being T3/T4 T-stage; (5) with at least one
Fig. 1 Study flow chart
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measurable tumor focus based on RECIST criteria and im-
aging diagnosis completed in 30 days before enrollment;
(6) expected survival time ≥3 months; (7) Karnofsky per-
formance status ≥60; (8) adequate hematopoietic function
of bone marrow in previous 7 days: hemoglobin ≥9 g/dL,
white blood cell count ≥3.0 × 109/L, neutrophils count
≥1.5 × 109/L, platelet count ≥100 × 109/L; (9) normal liver
and kidney function in previous 14 days: total bilirubin in
serum ≤1.5 times the upper limit of normal (ULN), ala-
nine transaminase and aspartate transaminase ≤3 times
ULN, creatinine ≤1.5 times ULN; (10) willing to take mea-
sures to prevent pregnancy.
Exclusion criteria
Exclusion criteria include: (1) with a history of radiation
treatment on head and neck; (2) with a history of other ma-
lignant tumors in past 5 years, except for healed skin basal
cell carcinoma and cervical carcinoma in situ; (3) with a
history of tumor chemotherapy; (4) receiving other effective
treatments; (5) having participated in other clinical trials in
4 weeks before enrollment; (6) with circulatory metastasis;
(7) with the histology subtype of squamous cell carcinoma;
(8) without measurable tumor focus, such as diffuse infiltra-
tive carcinoma; (9) cognitive impairment due to neursis or
psychosis; (10) cardiovascular and cerebrovascular diseases
with clinical significance, such as heart failure in NYHA
III/IV, uncontrolled coronary heart disease, myocardiopa-
thy, uncontrolled arrhythmia, uncontrolled hypertension,
history of myocardial infarction or cerebral infarction in the
past half year; (11) severe clinical infection in 14 days before
randomization including active pulmonary tuberculosis;
(12) human immunodeficiency virus infection, active hepa-
titis B or hepatitis C; (13) uncontrolled systemic disease,
such as diabetes mellitus; (14) with the history of interstitial
lung disease, such as interstitial pneumonia, pulmonary
fibrosis, or diagnosed as interstitial lung disease by chest X-
ray/CT image; (15) being pregnant or breast feeding.
Withdrawal of individual subjects
Subjects can withdraw from the study at any time for any
reason without any consequences. The investigator can
decide to let a subject out from the study for particular
medical reasons, for example, serious adverse events. For
every subject who decides to withdraw from the study, the
reasons for withdrawal should be recorded.
Randomization
Central randomization based on interactive web response
system (IWRS,Brightech Clinical Information Manage-
ment System) is carried out by Peking University Clinical
Research Institute, which is independent of the trial ad-
ministration office. The allocation sequence is computer-
generated 1:1 with dynamic randomization system and is
stratified by tumor size and neck lymph node metastasis.
Blinding
Allocation status cannot be blinded for the participants
and investigators due to different treatment methods
and the visibility of implanted I-125 seed in CT image.
However, the primary outcome (response to treatment)
will be evaluated by an independent assessment board.
Further, all statistical analysis will be done by a statisti-
cian in Peking University Clinical Research Institute who
is not affiliated with the trial.
Intervention –implanationt of I-125 seed
All subjects who are assigned to the intervention group
will receive I-125 seed permanent implantation in the
study. The operation of I-125 seed implantation will be
conducted at the department of Oral and Maxillofacial
Surgery, Peking University School and Hospital of Stoma-
tology. I-125 seeds will be ordered from the manufacturer
1–2 days before surgical operation. The placement of the
I-125 seed was determined from CT scans with the use of
a brachytherapy treatment planning system (BTPS; Beijing
Atom and High Technique Industries, Beijing, China).
The I-125 seed (model 6711; Jaco Pharmaceuticals Co.
Ltd., Zhejiang, China) activity was 0.9-1.0U per seed and
had a half-life of 59.6 days. Clinical target volume (CTV)
is defined as gross tumor volume (GTV) and its surround-
ing potential sub-clinical focus or microscopic focus, and
it is also divided as CTV1 and CTV2. CTV2, namely high
risk area, is defined as primary tumor and around 10 mm,
as well as drainage regions of involved lymph node.
CTV2, namely low risk area, is defined at 5 to 10 mm be-
yond CTV2 and lymphatic drainage area which should be
prevented by irradiation. The prescribed dose is 120 Gy
for CTV1 and 140 Gy for CTV2. And it is commonly as-
sumed that irradiation dose can accumulate to prescribed
dose in 6 months.
A CT scan is obtained one week after seeds implant-
ation. The CT images in combination with BTPS are
used to detect the location, number and isodose plot dis-
tribution of seeds. Re-implantation can be considered if
implant related deficiencies are identified, including
asymmetrical distribution, shedding or movement.
Control group – IMRT
All subjects who are assigned to the control group will
receive IMRT in the study, which is done at the depart-
ment of radiotherapy, Peking University Cancer Hospital
& Institute. Prescribed dose for planning target volume
and dose segmentation is computed with simultaneous
integrated boost modulated radiation therapy. In each
fraction of irradiation treatment, a specific dose is used
for different target volume during the entire course of
treatment. Totally, 70 Gy IMRT in 33 fractions (5 frac-
tions per week) are prescribed to the GTV, 60 Gy/33
fractions to CTV2, and 56 Gy/33 fractions to CTV1.
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Initial screening, assessment and follow-up
After providing informed consent, potential participants
will be asked standardized questions about their demo-
graphic characteristics and medical history. In addition,
physical examination, electrocardiography, routine urine
test, blood clotting function, urine β-human chorionic go-
nadotropin (HCG) for reproductive-age women, special-
ized examination, imaging examination, blood routine
examination and biochemistry, pathological diagnosis and
Karnofsky performance scale etc. will also be done and
used for checking inclusion/exclusion criteria (Fig. 2).
After randomization, eligible participants will receive
their treatment planning investigations and are followed-
up following the same schedule for both intervention
group and control group (Fig. 2) until recurrence, other
malignancy or death is confirmed. Treatment duration is
approximately 6–7 weeks for IMRT group. All the partici-
pants in both groups will be followed up at 2, 4, 6, 9, 12, 15,
18, 21 and 24 months after randomization, with specialized
examination, imaging examination, blood routine examin-
ation and biochemistry, Karnofsky performance scale, re-
cording of treatment and adverse events assessment done
Fig. 2 Observation, assessment, and follow-up schedule
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each time. Quality of life (QOL) scale will be assessed at 2,
6, 12, and 24 months. Forward radiation adverse reactions
will be evaluated at each follow-up appointment except at
2 months after randomization. In addition, pathological
diagnosis and PET/CT examination will be considered by
the investigator if imaging examinations are inadequate to
assess the primary outcome. Radioactive adverse events
were classified by The National Cancer Institute-Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
4.0 standard. Chronic radioactive damages were classified
by the criteria of Radiation Therapy Oncology Group/
European Organization for Research and Treatment of
Cancer (RTOG/EORTC), with common signs and severity
recorded.
Outcomes
Assessment of efficacy will be carried out by evaluation
of imaging examination at each follow-up. If applicable,
response to treatment will be evaluated according to the
RECIST criteria (version 1.1) and classified as complete
response (CR), partial response (PR), stable disease (SD)
and progressive disease (PD).
The primary outcome is estimated as the difference
between the intervention and the control group in
local control rate in 1 year. Local control rate is
judged to have been attained if there is no evidence
of PD at the primary site based on imaging findings
and clinical examination at follow-up. However, dis-
tant metastasis and second primary cancer are not
belonged to PD at the primary site in accordance
with RECIST criteria (version 1.1) [28].
Secondary outcomes are a) progression-free survival
(PFS), defined as the time from randomization to the
earliest occurrence of PD in whole body or death due
to any cause; PD in whole body includes PD at the
primary site, distant metastasis and second primary
cancer; b) overall survival (OS), from the date of
randomization to the date of death from any cause or
last date when the participant is alive; c) QOL evalu-
ated using the European Organization for Research and
Treatment of Cancer QOL Questionnaire (EORTC QLQ-
C30 and QLQ-H&N35) of Chinese version; and d) safety
of treatment.
Sample size estimation
Based on medical record of subjects with inoperable sal-
ivary gland malignancies in Peking University Cancer
Hospital & Institute and in Peking University School
and Hospital of Stomatology, local control rate in 1 year
was 81 % among subjects with I-125 PBT, and 45 %
among subjects with IMRT. Based on a difference of
36 % between groups on the primary outcome, a total of
72 participants are required to provide 90 % power, with
the use of two-sided significance level of 0.05. Assuming
a 20 % drop-out rate, approximately 90 subjects (or 45
subjects per arm) will be enrolled.
Statistical analysis
Analyses will be made using SAS statistical software
(version 9.3, SAS Institute, Cary, NC, USA) by re-
searchers at the Peking University Clinical Research In-
stitute. The primary analyses will be done on an intent-
to-treat basis and the last observation carry forward
(LOCF) is used for missing values. Descriptive statistics
will be used to summarize demographic and clinical
characteristics of subjects randomised to the interven-
tion and control group. The difference between two
groups on demographic and clinical characteristics, re-
sponse rate and drop-out rate will be compared using t-
tests (or Wilcoxon rank sum test) and chi-square test/
Fisher’s exact test as appropriate.
Primary outcome (local control rate in 1 year) analyses
will be carried out using chi-squared tests. The survival
curves (PFS and OS) are estimated by the Kaplan-Meier
method, and log-rank test is used to test the null hypoth-
esis that the respective curves are equal between the two
groups. A two-sided significance level of 5 % is used. A co-
variance model will be used to compare the QOL between
two groups by adjusting the difference of baseline. The in-
cidence of adverse events between two groups is com-
pared with the chi-square test/Fisher’s exact test.
Discussion
This trail is conducted to prospectively evaluate I-125
PBT for inoperable salivary gland malignancies in terms
of the efficacy, safety and the QOL.
Few studies have investigated the effect of I-125 PBT
for inoperable salivary gland malignancies and thus, the
evidence regarding I-125 PBT for inoperable salivary
gland malignancies is sparse. In recent years, we have
been exploring the effectiveness and feasibility of I-125
PBT for inoperable salivary gland malignancies. Our pre-
vious studies displayed that I-125 PBT may be one of
the most promising treatment for inoperable salivary
gland malignancies, but the evidence of these results is
not sufficient enough due to limited number of observa-
tional studies [23, 24]. The proposed study is a rando-
mised controlled single-centre trial conducted among
subjects with inoperable salivary gland malignancies. To
our knowledge, it is the first trial to investigate the efficacy
of I-125 PBT for subjects with inoperable salivary gland ma-
lignancies, and will add to the knowledge base in a number
of ways. Not only tumor cells, but also normal cells, are
simultaneously killed by radiotherapy. Many side effects are
often observed during and after radiotherapy, including
lower white blood cell count, general weakness and loss of
appetite, mucositis, xerostomia, hearing loss, radiation
dermatitis, fibrosis, osteoradionecrosis of the mandible, and
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injury to optic apparatus. These side effects may lower the
QOL of these subjects. In addition to effectiveness, we also
investigate safety and QOL. These findings will help to sys-
tematically evaluate clinical application value of I-125 PBT.
We set a comparison treatment as the control arm,
which will help us to assess the efficacy of I-125 PBT. We
choose IMRT as the control arm because of its fewer side
effects. IMRT is more precise radiotherapy modality
which helps to reduce normal tissue damages compared
with conventional external radiotherapy. Although there
was no evidence that IMRT could significantly improve
the LCR, many studies had shown that IMRT could sig-
nificantly reduce toxic side effects when used in the head
and neck cancer region [29]. This IMRT comparison arm
can help to protect patient and improve compliance.
On account of the low prevalence, we will recruit pa-
tient with relatively inclusive entry criteria, and anticipate
recruiting subjects across the spectrum of histologies and
from various inoperable circumstances. These features will
improve the generalisability of our findings. On the other
hand, subjects will constitute a heterogeneous group, and
this could weaken the power of our trial. We have taken a
number of steps to reduce selection bias. The trial does
not include all relevant subjects (e.g., some subjects are
excluded, such as with subtotal resection, T1/T2-staged,
and metastatic cancer). In addition, subjects are stratified
by tumor size (≤4 cm vs. >4 cm) and neck lymph node
metastasis (yes vs. no) to balance random allocation.
The treatment allocation cannot be blinded for partici-
pants and study staffs due to different procedures and the
visibility of implanted I-125 seed in CT image, which is of
course a limitation. However, to reduce observer bias in
assessment, all assessment data are collected by research
assistants who did not participate in the study; in addition,
the primary outcome (response to treatment) will be eval-
uated by independent assessment board. Further, all statis-
tical analysis will be done by a statistician at Peking
University Clinical Research Institute who is not affiliated
with the trial.
Conclusion
The proposed study aims to investigate whether subjects
with inoperable salivary gland malignancies will benefit
from iodine-125 seed permanent brachytherapy. We will
also study the side effects of such treatment.
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